8-K: Reviva Pharmaceuticals Reports Q2 2024 Financial Results and Provides Business Update

Reviva Pharmaceuticals announced its second quarter 2024 financial results, highlighted by progress in its brilaroxazine clinical program and expansion of its patent portfolio.

Summary

• Reviva Pharmaceuticals reported a net loss of approximately $7.9 million, or $0.26 per share, for the three months ended June 30, 2024, compared to a net loss of approximately $11.7 million, or $0.52 per share, for the same period in 2023.
• The company's net loss for the six months ended June 30, 2024, was approximately $15.3 million, or $0.51 per share, compared to a net loss of approximately $18.6 million, or $0.84 per share, for the same period in 2023.
• As of June 30, 2024, Reviva's cash totaled approximately $6.2 million, a decrease from approximately $23.4 million as of December 31, 2023.
• The company is progressing with its brilaroxazine program, with topline data from a 1-year open-label extension trial expected in Q4 2024 and the initiation of the registrational RECOVER-2 trial in schizophrenia expected in Q3 2024.
• Reviva has also expanded its intellectual property portfolio with patents granted in Europe and the U.S. for brilaroxazine in pulmonary hypertension and idiopathic pulmonary fibrosis, respectively.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the progress in clinical trials, patent grants, and reduced losses. However, the significant decrease in cash reserves and ongoing losses temper the overall outlook.

Positives

• The company's net loss decreased year-over-year for both the quarter and six-month periods.
• Reviva has secured key patents in Europe and the U.S. for brilaroxazine, expanding its intellectual property protection.
• The clinical program for brilaroxazine is progressing as expected, with key trials on track.
• The company has received Orphan Drug Designation from the FDA for brilaroxazine in the treatment of both IPF and PAH.
• The company has aligned with the FDA on the registrational Phase 3 program for brilaroxazine in schizophrenia.

Negatives

• The company's cash balance has significantly decreased from $23.4 million at the end of 2023 to $6.2 million as of June 30, 2024.
• The company continues to operate at a loss, with a net loss of $7.9 million for the quarter and $15.3 million for the six-month period.

Risks

• The company's current cash balance of $6.2 million may not be sufficient to fund operations until the next major milestone.
• Clinical trial outcomes are uncertain, and delays or negative results could impact the company's prospects.
• The company is dependent on the success of its brilaroxazine program, and any setbacks could have a significant impact.
• The company is subject to regulatory risks, including the possibility of not receiving regulatory approvals for its drug candidates.
• The company faces competition from other pharmaceutical companies developing treatments for similar conditions.

Future Outlook

The company anticipates several key milestones, including the initiation of the RECOVER-2 trial in Q3 2024, topline data from the 1-year open-label extension trial in Q4 2024, topline data from the RECOVER-2 trial in Q4 2025, and a potential NDA submission for brilaroxazine in schizophrenia targeted for Q1 2026. They also plan to pursue partnership opportunities and submit an IND for a liposomal-gel formulation of brilaroxazine in psoriasis in 2025.

Management Comments

• Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva, stated that the late-stage brilaroxazine program continues to advance.
• He also noted the expansion of intellectual property for brilaroxazine to cover additional large markets for PH and IPF.
• He believes brilaroxazine continues to show a differentiated safety and efficacy profile in the over 800 patients with schizophrenia treated to date in their trials.

Industry Context

This announcement is relevant to the pharmaceutical industry, particularly in the areas of central nervous system, inflammatory, and cardiometabolic diseases. The progress of brilaroxazine in schizophrenia, pulmonary hypertension, and idiopathic pulmonary fibrosis positions Reviva as a potential player in these markets. The company's focus on novel chemical entities and its patent portfolio are also significant in the competitive landscape.

Comparison to Industry Standards

• Reviva's reported net loss of $7.9 million for Q2 2024 is an improvement compared to the $11.7 million loss in Q2 2023, indicating progress in managing expenses, however, the cash burn rate is still high.
• The company's cash balance of $6.2 million is relatively low for a late-stage pharmaceutical company, especially considering the ongoing clinical trials and research expenses. This is lower than many comparable companies at this stage of development.
• The successful granting of patents in Europe and the U.S. for brilaroxazine is a positive development, as it provides intellectual property protection and potential market exclusivity. This is comparable to other companies that have successfully patented their drug candidates.
• The Orphan Drug Designation for brilaroxazine in IPF and PAH is a positive step, as it provides potential market exclusivity and other benefits. This is a common strategy for companies developing treatments for rare diseases.
• The timeline for the RECOVER-2 trial and NDA submission is consistent with industry standards for late-stage clinical development. However, the company will need to execute well to meet these timelines.

Stakeholder Impact

• Shareholders may be encouraged by the progress in clinical trials and patent grants, but concerned about the decreasing cash balance.
• Employees may be motivated by the advancement of the company's pipeline and the potential for future success.
• Patients may benefit from the development of new treatments for schizophrenia, pulmonary hypertension, and idiopathic pulmonary fibrosis.
• Creditors may be concerned about the company's decreasing cash balance and its ability to meet its obligations.

Next Steps

• Initiate the registrational Phase 3 RECOVER-2 trial in Q3 2024.
• Complete the 12-month long-term safety study in Q4 2024.
• Release topline data from the 1-year open-label extension trial in Q4 2024.
• Release topline data from the RECOVER-2 trial in Q4 2025.
• Submit a potential NDA for brilaroxazine in schizophrenia targeted for Q1 2026.
• Submit an IND for a liposomal-gel formulation of brilaroxazine in psoriasis in 2025.
• Pursue partnership opportunities for the development of the pipeline.

Key Dates

Keywords

brilaroxazine, schizophrenia, pulmonary hypertension, idiopathic pulmonary fibrosis, clinical trials, patents, orphan drug designation, RECOVER-2, FDA, pharmaceuticals